The economics of the penicillin manufacturing Europe still sustains come down to a squeeze that Sandoz describes plainly: buyers choose on price, imported ingredients are cheap, and a fermentation plant in Austria is costly to run. A wire-service report published on 21 October 2026 sets out that argument around the Kundl plant, which Sandoz calls the only European site making penicillin from start to finish. This article looks at the commercial logic and at what is, and is not, established.
Key takeaways on penicillin manufacturing Europe’s economics
- Sandoz says procurement based on lowest price, plus competition, prevents it from raising prices, according to the report.
- Sandoz CEO Richard Saynor is reported as saying antibiotics need more pricing power, noting that a pack of antibiotics sells for less than a candy bar in Switzerland or the UK.
- China’s share of EU imports of penicillins and derivatives rose to 86% last year from 44% in 2019, per Eurostat figures cited in the report.
- Sandoz says Kundl’s capacity is not commercially sustainable without higher government payments, and has filed an anti-dumping complaint with the Commission.
- None of these claims has been tested by a regulator, and penicillin manufacturing Europe-wide has no announced remedy yet.
The cost side of penicillin manufacturing Europe depends on
According to the report, Kundl makes penicillin by fermentation in large metal vats, a process that is energy-intensive, with energy use comparable to Innsbruck, a city of more than 130,000 people. The report cites IEA data showing electricity prices for energy-intensive EU industry averaged nearly 50% above China’s in 2025. For a plant of this kind, energy, scale and utilisation are major drivers of unit cost, which is general industry logic rather than a Sandoz figure.
The site employs more than 2,000 people, per the report, and has received public support: a €200 million expansion about three years ago that included €50 million in public funds, and a €28.3 million Commission-approved aid decision in 2023 for an expansion that lifted capacity by 20%. Those amounts are as reported, and we have not verified the aid decisions independently.
The price side: low-cost procurement
Sandoz argues that when health systems buy on the lowest price, a producer with higher costs cannot pass them on. The company also says that up to 90% of global antibiotic active ingredients are made outside Europe, mainly in China or in India using Chinese chemicals. These are company statements. The Sandoz website is the place to check its own positions, and we have not used it for any figure not attributed here.
The Chinese foreign ministry, as quoted in the report, says trade differences should be resolved through dialogue and opposes all forms of trade protectionism. The allegation of below-cost sales is therefore contested in principle, and only an investigation would examine cost and price data in detail.
General background: why ingredient sourcing matters for penicillin manufacturing Europe
Active pharmaceutical ingredients are the drug substances that go into finished medicines. For penicillins, the ingredient is made by fermentation and chemistry before being formulated into tablets or powders. If ingredient supply concentrates in one country, finished-dose producers elsewhere become dependent on it, which is why the World Health Organization frames antibiotic access as part of its broader antimicrobial resistance work. For market sizing context, see our earlier coverage: Penicillin Active Pharmaceutical Ingredients Market Revenue, Trends, and Strategic Insights by 2032.
Our analysis: who pays for resilience
In our assessment, the penicillin manufacturing Europe wants to keep is a public good that the current price system does not pay for. If procurement rewards only the cheapest ingredient, the system will tend to lose domestic capacity, and a resilience premium would have to come from somewhere: higher prices, subsidies, or stockpiling. Each option has a cost that falls on someone, whether health budgets, taxpayers or manufacturers.
A trade remedy would be a different lever. It would raise the price of imported ingredients if the Commission found dumping, but it would not by itself create demand for European output. We flag this as analysis, and note that Sandoz is an interested party. See our pharmaceuticals coverage for related reporting.
It is also worth separating a company that wants a better price from a system that needs one. The first is a negotiating position, and the second is a policy judgement. The report gives enough to understand the first, but not enough to settle the second, because it contains no output volumes for Kundl and no cost evidence that an outsider can check.
What is not disclosed about penicillin manufacturing Europe’s economics
- Kundl’s output, margins and utilisation.
- The cost evidence behind the allegation of below-cost Chinese sales.
- The size of the “higher government payments” that Sandoz says it needs.
- Whether the Commission will open an investigation and when.
Risks and caveats for penicillin manufacturing Europe
The report is a single wire-service account built on company statements, trade data and named commentators. It describes no regulatory finding. The Commission declined to comment, and the report says a probe is expected but its timing is unclear because of a backlog. The EU trade commissioner has, in another sector, struck a deal with Beijing rather than imposing tariffs, which shows that duties are not the only possible result. Nothing here is investment advice.
There is a further caveat on language. Terms such as dumping and below-cost have legal meanings in trade law, and they are allegations until a Commission investigation reaches a finding. Policy for penicillin manufacturing Europe could also move in other directions, such as procurement reform or targeted aid.
What to watch next in penicillin manufacturing Europe
- Whether the Commission opens a proceeding, and how it describes the product scope.
- Any change to national procurement rules that values security of supply, not just price.
- Further state-aid decisions affecting Kundl.
- The next EU trade policy updates on ongoing investigations.
FAQ
Why does Sandoz say Kundl is under pressure?
It says low-price procurement and cheap imported ingredients leave the plant commercially unsustainable without higher government payments.
Is penicillin manufacturing Europe’s main supplier Sandoz?
The report calls Kundl Europe’s only fully integrated penicillin plant. It does not give market-share figures for European supply.
Has a remedy been decided?
No. A complaint has been filed, but no investigation or duty has been reported.
How we reported this: we relied on a wire-service report and on official sources for background, attributing each figure. Calculations are labelled as ours. Last updated 23 October 2026. This is news reporting and not advice.
